NEWS & EVENTS
Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity
October 26, 2023
Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the potential to improve human Longevity.
The World Health Organization estimates 650 million obese and 537 million Type 2 Diabetic patients worldwide. The World Obesity Federation predicts that 51% of the world — more than 4 billion people — will be obese or overweight within the next 12 years. These rates are alarming, especially among youth and adolescents. In the United States alone, more than 100 million people (about four in 10) are obese, and 37 million are diabetic (about 1 in 10), 90-95% of whom are Type 2, according to the Centers for Disease Control and Prevention. While recently approved drugs for treating Type 2 diabetes have also been found effective for weight loss, significant toxicity and drug administration complications remain.
“We believe that our novel small molecule therapeutics delivered orally can address some of the toxicity and delivery complications associated with today’s treatments,” said Dr. David J. Bearss, CEO and co-founder of Biolexis Therapeutics. “With the launch of Metabolexis, we have an opportunity to address this immense need by providing clinically effective, easily administered, and economically viable treatments that improve the lives of these patients.”
The Metabolexis pipeline includes isoform-specific activators of AMPK, aGLP-1/GLP-1R agonists, and mTORC1 inhibitors with plans to file Investigational New Drug Applications (INDs) for all three agents by the end of Q4 2024 and to initiate First-In-Human Phase I safety clinical trials in Q1 2025. Utilizing Biolexis’ MolecuLern™ process, the company has identified lead candidates currently in pre-clinical development.
MolecuLern is an AI-enabled drug discovery process that leverages empirical/wet lab data-driven models trained on Biolexis’ curated and proprietary library, including physical and virtual synthesis-ready fragments and NCEs, to identify lead molecules targeting any class of protein.
This innovative and expedited process results in candidates with drug-like characteristics, reducing development costs, increasing the potential for clinical trial effectiveness, and significantly accelerating the drug discovery time frame.
“Obesity-related conditions, including Type-2 Diabetes, Cardiometabolic, Stroke, and age-related diseases, continue to be crucial issues in our communities,” said Dr. Hariprasad Vankayalapati, CSO and co-founder of Biolexis Therapeutics. “As we continue to research, develop, and implement innovative methods to address critical unmet medical needs, we believe our work in activating AMPK, agonizing GLP-1, and inhibiting mTORC1 targets will expand treatment options for patients with these and other metabolic disorders.”
Metabolexis will focus on targeting these important conditions with the goal to eliminate the presence of the major chronic conditions associated with aging. Aging is linked to the gradual deterioration in biological functions occurring in most tissues. Aging in specific tissues leads to a variety of disorders, including neurodegeneration, obesity, diabetes, cardiovascular diseases and cancer. The work at Metabolexis will focus on targeting known regulators and pathways that control the aging process and will develop drugs intended to improve the health of the aging population.
For more information, please visit www.biolexistx.com.
About Biolexis
Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLern AI-enabled drug discovery process.
SOCIETY OF NEUROSCIENCE ANNUAL MEETING TO BE HELD
November 11-15, 2023
Biolexis Therapeutics Scientific Team participates and present their pre-clinical stage small molecule HDAC6 inhibitor program for ALS indication at the “SfN” (Society of Neuroscience) Annual Meeting to be held on Nov 11-15, 2023 – Walter E. Washington Convention Center in Washington, D.C.
https://www.sfn.org/meetings/neuroscience-2023
Abstract Title: Development of a Novel, Orally Active, Brain Penetrable HDAC6 Inhibitors Shows a Therapeutic Potential for Amyotrophic Lateral Sclerosis (ALS)
Session Title: ALS: Non-Human Models
Session Type: Poster | Abstract Control Number: 2773
Session Number: PSTR200 | Presentation Number: PSTR200.26
Session Date and Time: 11/13/2023 8:00:00 AM – 11/13/2023 12:00:00 PM
Location/Room: WCC Halls A-C | Presentation Time: Mon. Nov. 13, 2023, 9:00 AM – 10:00 AM
INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS
October 11-15, 2023
Biolexis Therapeutics Scientific Team participates and present their IND stage small molecule CDK9 inhibitor program for Pancreatic Cancers indications at The “AACR-NCI-EORTC” International Conference on Molecular Targets and Cancer Therapeutics to be held on Oct 11-15, 2023 – Haynes Convention Center, Boston, Massachusetts
Abstract title: Development of BLX-3030, A Potent, Selective, Orally Available CDK9i shows promise in Pancreatic Ductal Adenocarcinoma (PDAC) Models
Poster number:LB_C13 | Session: Poster Session C
Session location: Level 2, Exhibit Hall D
Session date and time: Saturday, October 14 | 12:30 pm-4:00 pm
14th Annual World Cancer Congress
July 22-24, 2023
Biolexis Therapeutics CSO invited to Chair Cancer Immunology & Immunotherapy session and present MolecuLern technology at 14th Annual World Cancer Congress – WCC 11: Cancer Immunology & Immunotherapy on July 22-24, 2023, at Barcelona, Spain.
22nd Annual Bio-IT World Conference & Expo
May 16-18, 2023
Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at 22nd Annual Bio-IT World Conference & Expo taking place May 16-18, 2023, in Boston, MA.
Ai-Driven Drug Development Summit
April 26-27, 2023
Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at Ai-Driven Drug Development Summit Europe on April 26-27, 2023, in London.
AI Driven Drug Development Summit Europe 2023 (aidrugdevelopmentsummiteu.com)
AACR (American Association of Cancer Research) Annual Meeting
April 14-19, 2023
Biolexis management participates and presents at the AACR (American Association of Cancer Research) Annual Meeting on April 14-19, 2023 – Orange County Convention Center, Orlando, Florida.
AACR 2022 Annual Meeting
April 8-13, 2023
Biolexis Therapeutics Inc., a leader in bio-tech research and creator of the FIELDS™ process, today announced that data highlighting an orally available, CDK9 selective small molecule inhibitor showing promise in n-Myc-driven neuroendocrine prostate cancers (NEPC) was presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.
2023 Annual San Antonio Drug Discovery Symposium
April 10-11, 2023
Biolexis Therapeutics CSO invited to present company MolecuLern™ technology at 2023 Annual San Antonio Drug Discovery Symposium held at Greehey Children’s Cancer Research Institute of University of Texas Health San Antonio.
https://research.utsa.edu/events/2023/04/03-cidd-annual-drug-discovery-symposium.html
AACR (American Association of Cancer Research) Annual Meeting
April 8-13, 2023
Biolexis management participated and presented pre-clinical data on CDK9 inhibitor at the AACR (American Association of Cancer Research) Annual Meeting on April 8-13, 2022, Ernest N. Morial Convention Center New Orleans, Louisiana.
B137 / 13 – Orally available, CDK9 selective, small molecule inhibitors shows promise in n-Myc-driven neuroendocrine prostate cancers (NEPC)
Session LBPO.MCB02 – Late-Breaking Research: Molecular/Cellular Biology and Genetics 2.
Next Generation Kinase Inhibitors Summit
February 22-23, 2023
Biolexis Therapeutics Business Development team participated 2nd Next Generation Kinase Inhibitors Summit was held on February 22-23, 2023, in Boston.
Precision in Drug Discovery & Preclinical Summit 2022
November 14-15, 2022
Biolexis Therapeutics Management participates and presents their MolecuLern technology at Precision in Drug Discovery & Preclinical Summit 2022 on Nov 14-15, 2022, San Francisco CA, US.
10th Annual Drug Discovery Strategic Summit
Oct 27-28, 2023
Biolexis Therapeutics Management participates and presents their MolecuLern technology at 10th Drug Discovery Strategic Summit, Oct 27th – 28th 2022, San Francisco CA, US
RESI Conference (Redefining Early-Stage Investments)
September 21-22, 2022
Biolexis Therapeutics Business Development Director Kyle Medley participated in RESI Conference (Redefining Early-Stage Investments), Boston, MA on Sep 21-22, 2022.
PRESS RELEASES
Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development
Led by Clarke Capital, the new funding round will accelerate the company’s drug discovery pipeline
American Fork, UT – November 29, 2023— Biolexis Therapeutics, Inc., a clinical stage AI-driven drug discovery company, announced today the successful closure of a $10 million Series A funding round. The investment was led by Clarke Capital, a prominent institutional investor and alternative investment firm.
The new funding will advance Biolexis’ development pipeline which includes a range of promising metabolic drug candidates. These drugs have the potential to tackle various metabolic disorders that affect millions of people worldwide and are linked to significant health complications such as obesity and diabetes.
“This financial backing from Clarke Capital is a testament to the potential of our metabolic drug portfolio,” said David Bearss, CEO of Biolexis. “Our science is on point and our team is ready to tackle the unmet needs within the metabolic disorder spectrum. With Clarke Capital’s support, we’re in a strong position to accelerate our drug development pipeline and move closer to bringing our solutions to patients.”
The Series A funding marks a significant milestone for Biolexis but also marks Clarke’s return to partner with Drs. Bearss and Vankayalapati, having been a major investor in their first company, Montigen Pharmaceuticals, a decade and a half ago before it was sold to a publicly traded company. The reteaming will allow the company to expand its operations and accelerate the clinical development of its key drug candidates. With the prevalence of metabolic diseases on the rise and current treatments in limited supply, the need for new and effective treatment options is more urgent than ever.
“At Clarke Capital, we’re committed to investing in companies poised to make a significant impact on healthcare,” said James Clarke, CEO of Clarke Capital. “Biolexis’ impressive approach to addressing metabolic disorders and other treatment-resistant conditions has the potential to change lives. We are overjoyed to support their mission and look forward to seeing the results of their groundbreaking work.”
To date, Drs. Bearss and Vankayalapati have filed more than 20 Investigational New Drugs (INDs) and have secured more than 100 patents. Using its unique AI-driven MolecuLern™ process, Biolexis has 40 active programs in discovery and 10 pipeline programs in the IND-enabling stages of development. The process, which targets any class of protein to identify novel chemical entities (NCEs) with drug-like characteristics and real wet-lab data validation, reduces the discovery and development timeline from years to months.
To learn more about Biolexis visit www.biolexistx.com.
###
About Biolexis
Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLern AI-enabled drug discovery process.
About Clarke Capital
Clarke Capital is an alternative asset investment firm with a robust portfolio of successful companies. Clarke takes a “hands on” approach when partnering with visionary entrepreneurs with an aim to create and grow high-potential, industry transformative companies.
Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity
October 26, 2023
Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the potential to improve human Longevity.
The World Health Organization estimates 650 million obese and 537 million Type 2 Diabetic patients worldwide. The World Obesity Federation predicts that 51% of the world — more than 4 billion people — will be obese or overweight within the next 12 years. These rates are alarming, especially among youth and adolescents. In the United States alone, more than 100 million people (about four in 10) are obese, and 37 million are diabetic (about 1 in 10), 90-95% of whom are Type 2, according to the Centers for Disease Control and Prevention. While recently approved drugs for treating Type 2 diabetes have also been found effective for weight loss, significant toxicity and drug administration complications remain.
“We believe that our novel small molecule therapeutics delivered orally can address some of the toxicity and delivery complications associated with today’s treatments,” said Dr. David J. Bearss, CEO and co-founder of Biolexis Therapeutics. “With the launch of Metabolexis, we have an opportunity to address this immense need by providing clinically effective, easily administered, and economically viable treatments that improve the lives of these patients.”
The Metabolexis pipeline includes isoform-specific activators of AMPK, aGLP-1/GLP-1R agonists, and mTORC1 inhibitors with plans to file Investigational New Drug Applications (INDs) for all three agents by the end of Q4 2024 and to initiate First-In-Human Phase I safety clinical trials in Q1 2025. Utilizing Biolexis’ MolecuLern™ process, the company has identified lead candidates currently in pre-clinical development.
MolecuLern is an AI-enabled drug discovery process that leverages empirical/wet lab data-driven models trained on Biolexis’ curated and proprietary library, including physical and virtual synthesis-ready fragments and NCEs, to identify lead molecules targeting any class of protein.
This innovative and expedited process results in candidates with drug-like characteristics, reducing development costs, increasing the potential for clinical trial effectiveness, and significantly accelerating the drug discovery time frame.
“Obesity-related conditions, including Type-2 Diabetes, Cardiometabolic, Stroke, and age-related diseases, continue to be crucial issues in our communities,” said Dr. Hariprasad Vankayalapati, CSO and co-founder of Biolexis Therapeutics. “As we continue to research, develop, and implement innovative methods to address critical unmet medical needs, we believe our work in activating AMPK, agonizing GLP-1, and inhibiting mTORC1 targets will expand treatment options for patients with these and other metabolic disorders.”
Metabolexis will focus on targeting these important conditions with the goal to eliminate the presence of the major chronic conditions associated with aging. Aging is linked to the gradual deterioration in biological functions occurring in most tissues. Aging in specific tissues leads to a variety of disorders, including neurodegeneration, obesity, diabetes, cardiovascular diseases and cancer. The work at Metabolexis will focus on targeting known regulators and pathways that control the aging process and will develop drugs intended to improve the health of the aging population.
For more information, please visit www.biolexistx.com.
About Biolexis
Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLern AI-enabled drug discovery process.
Contact Us
Contact Us
CORPORATE HEADQUARTERS
858 S Auto Mall Dr. #102
American Fork, UT 84003
United States
Ph: 801-692-3655 info@biolexistx.com
